ARISTADA INITIO™ for Treatment of Schizophrenia

Dr. David Walling, Ph.D., CEO, psychologist and principal investigator at CNS Trials, a clinical research provider, discusses the recent FDA approval (June 2018) of ARISTADA INITIO™ for the initiation of ARISTADA® (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults.

Dr. Walling serves as Chief Executive Officer and Principal Investigator for CNS. He has participated as a lead or co-investigator in more than 200 clinical studies, with many focusing on schizophrenia and schizoaffective disorder. Dr. Walling has authored numerous articles in leading scientific journals, including the American Journal of Psychiatry, American Journal of Psychotherapy, and Journal of Nervous and Mental Disease.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.